DPNCheck can improve the effectiveness of neuropathy detection programs and is ideal for:
The prevalence of peripheral neuropathy in the general population is 10% and in patients over 65 it increases up to 25%1. Over 50% of patients with diabetes will develop neuropathy2. The rate of diagnosed neuropathy is often much lower than the prevalence rate resulting in unidentified risk.
DPNCheck has been clinically validated in numerous peer-reviewed journal publications and clinical conference presentations. Click here to view the complete list.
1. Mold JW, Vesely SK, Keyl BA, Schenk JB, Roberts M. The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients. J Am Board Fam Pract. 2004;17(5):309-318.
2. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154
3. Perkins, et al. Simple Screening tests for Peripheral Neuropathy in the Diabetes Clinic. Diabetes Care. 24: 250-256, 2001.